'Carbonyl stress' and dialysis-related amyloidosis

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 1, 2000, Pages 25-28

  Miyata, Toshio ^a   Ueda, Y ^a   Saito, A ^a   Kurokawa, K ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED LIPOXIDATION END PRODUCT; AMYLOID; BETA 2 MICROGLOBULIN; CARBONYL DERIVATIVE; PENTOSIDINE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ARTHROPATHY; CONFERENCE PAPER; DIALYSIS; GLYCATION; HUMAN; HYPERGLYCEMIA; LIPID OXIDATION; MACROPHAGE; MONOCYTE; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; SYNOVIOCYTE; UREMIA;

EID: 0033997047     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027959     Document Type: Conference Paper

References (38)

1. 2-Microglobulin in renal disease. J Am Soc Nephrol (in press)
2. 2-microglobulin amyloidosis in haemodialysis: a prospective post-mortem study. Kidney Int 1997; 51: 1928-1932
3. Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H, Mimura N. Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 1992; 41: 1646-1652
4. Argiles A, Mourad G, Kerr PG, Garcia M, Collins B, Demaille JG. Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrol Dial Transplant 1994, 9: 662-667
5. 2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition. Clin Nephrol 1988; 30: 158-163
6. Argiles A, Derancourt J, Jauregui-Adell J, Minon C, Demaille JG. Biochemical characterization of serum and urinary beta 2 microglobulin in end-stage renal disease patients. Nephrol Dial Transplant 1992; 7: 1106-1110
7. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-1252
8. 2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996; 93: 2353-2358
9. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
10. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-2469
11. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 1992; 41: 1286-1292
12. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-2478
13. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik K, Delaney V, Friedman EA. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842
14. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Yperesle de Strihou C, Maeda K. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-1206
15. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Yperesle de Strihou C. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997; 51: 880-887
16. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989; 264: 21597-21602
17. ε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-4894
18. ε-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997; 52: 1064-1067
19. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997; 12: 255-258
20. Baynes JW. Perspectives in diabetes: role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412
21. ε-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990; 29: 10964-10970
22. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11654-11660
23. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of protein by glucose. Biochemistry 1995; 34: 3702-3709
24. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170-1181
25. Canestrari F, Galli F, Giorgini A, Albertini MC, Galiotta P, Pascucci M, Bossu M. Erythrocyte redox state in uremic anemia: effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994; 91: 187-193
26. Kumano K, Yokota S, Go M, Suyama K, Sakai T, Era S, Sogami M. Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 1992; 8: 127-130
27. Yeung JH. Effects of glycerol-induced acute renal failure on tissue glutathione and glutathione-dependent enzymes in the rat. Methods Find Exp Clin Pharmacol 1991; 13: 23-28
28. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313 T. Miyata et al.
29. Esterbauer H, Schuer RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehyde. Free Radical Biol Med 1991; 11: 81-128
30. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in non-enzymatic biochemistry in uremia: origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999; 55: 389-399
31. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 1997; 100: 2995-3004
32. Stadtman ER. Protein oxidation and aging. Science 1992; 257: 1220-1224
33. 2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implication for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996; 98: 1088-1094
34. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1. J Clin Invest 1994; 93: 521-528
35. 2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 1994; 201: 1235-1241
36. 2-microglobulin modified with the advanced glycation end products. Kidney Int 1996; 49: 538-550
37. 2-microglobulin in the pathogenesis of bone lesions in dialysis associated amyloidosis. Nephrol Dial Transplant 1996; 11: 86-90
38. Miyata T, Notoya K, Yoshida K, Horie K, Kurokawa K, Maeda K, Taketomi S. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997; 8: 260-270